Options for Prevention of T Cell Alloactivation by Blood Transfusions

  • F. H. J. Claas
  • H. S. de Koster
  • E. L. Lagaaij
  • J. J. van Rood
Part of the Developments in Hematology and Immunology book series (DIHI, volume 28)


Blood transfusions may have opposite immunological effects. They can either lead to immunization of the recipient or induce immunological tolerance. The latter effect might be very helpful for clinical transplantation, whereas immunization is generally considered to be a negative effect for both patients in need for further blood transfusions and for patients waiting for an organ transplantation. The most easy parameter for immunization is the presence of circulating alloantibodies. In HLA-alloimmunization, it is known that most of these alloantibodies are of the IgG type, which is a clear indication that also T cell activation has taken place during the immunization process. A pivotal role in allorecognition is played by CD4+ T cells, which recognize the foreign HLA class II molecules of the transfused cells. Once these CD4+ T cells are properly triggered by alloantigen presenting cells in the first phase of the immune response, they will, either directly or indirectly via cytokines and other factors, initiate and facilitate the actual effector processes of the immune response leading to IgG antibody formation and maturation of cytotoxic T lymphocytes. Therefore one can expect that prevention of activation of these CD4+ T cells may be an effective way to prevent alloimmunization. Induction of tolerance, is another possible strategy to prevent alloimmunization. For the induction of tolerance, we hypothesize that not prevention of activation but activation of certain (allopeptide specific) CD4+ T cells might be essential.


Blood Transfusion Natural Killer Activity Kidney Graft Survival Natural Killer Cell Recognition Donor Peptide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Dausset J. Leuco-agglutinins. IV. Leuco-agglutinins and blood transfusion. Vox Sang 1954;4:190–8.Google Scholar
  2. 2.
    Van Rood JJ, Eernisse JG, van Leeuwen A. Leucocyte antibodies in sera from pregnant women. Nature 1958,181:1735–6.CrossRefGoogle Scholar
  3. 3.
    Claas FHJ, Smeenk RJT, Schmidt R, van Steenbrugge GJ, Eernisse JG. Alloimmunization against the MHC antigens after platelet transfusion is due to contaminating leukocytes in the platelet suspension. Exp Hematol 1981;9:84–9.PubMedGoogle Scholar
  4. 4.
    Eernisse JG, Brand A. Prevention of platelet refractoriness due to HLA antibodies by administration of leukocyte poor blood components. Exp Hematol 1981;9:77–83.PubMedGoogle Scholar
  5. 5.
    Deeg HJ. Transfusion with a tan: Prevention of alloimmunization by UV irradiation. Transfusion 1989;29:453–8.CrossRefGoogle Scholar
  6. 6.
    Pamphillon DH, Corbin SA, Saunders J, Tandy NP. Applications of ultraviolet light in the preparation of platelet concentrates. Transfusion 1989;29:379–83.CrossRefGoogle Scholar
  7. 7.
    Haisa M, et al. Donor-specific transfusion (DST) with intermittent administration of azathioprine induces suppressor T cells and MLR-inhibiting factors without sensitization. Transplant Proc 1989;21:1814–7.PubMedGoogle Scholar
  8. 8.
    Glass NR, Miller DT, Sollinger HW, Beizer FO. Comparative analysis of the DST and imuran-plus DST protocols for life donor renal transplantation. Transplantation 1983;36:636–41.PubMedCrossRefGoogle Scholar
  9. 9.
    Susal C, Terness P, Opelz G. An experimental model for preventing alloimmunization against platelet transfusions by pretreatment with antibody-coated cells. Vox Sang 1990;59:209–15.PubMedCrossRefGoogle Scholar
  10. 10.
    Opelz G, Sengar DPS, Mickey MR, Terasaki PI. Effect of blood transfusions on subsequent kidney transplants. Transplant Proc 1973;5:253–9.PubMedGoogle Scholar
  11. 11.
    Lundgren G, Albrechtsen D, Flatmark A, et al. HLA-matching and pretransplant blood transfusions in cadaveric renal transplantation, a changing picture with cyclosporin. Lancet 1986;ii:66–8.CrossRefGoogle Scholar
  12. 12.
    Opelz G. Improved kidney graft survival in non-transfused recipients. Transplant Proc 1987;19:149–52.PubMedGoogle Scholar
  13. 13.
    Persijn GG, van Leeuwen A, Parlevliet J, et al. Two major factors influencing kidney graft survival in Eurotransplant: HLA-DR matching and blood transfusion(s). Transplant Proc 1981;13:150–4.PubMedGoogle Scholar
  14. 14.
    Voogt PJ, van de Velde CJH, Brand A, et al. Perioperative blood transfusions and cancer prognosis: Different effects of blood transfusion on prognosis of colon and breast cancer patients. Cancer 1987;59:836–43.PubMedCrossRefGoogle Scholar
  15. 15.
    Wu H-S, Little AG. Perioperative blood transfusions and cancer recurrence. J Clin Oncol 1988;6:1348–54.PubMedGoogle Scholar
  16. 16.
    Lagaaij EL, Henneman JPH, Ruigrok M, et al. Effect of one HLA-DR antigen matched and completely HLA-DR mismatched blood transfusions on survival of heart and kidney allografts. N Engl J Med 1989;321:701–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Vandekerckhove BAE, van Bree S, Zhang LI, Datema G, Zantvoort F, Claas FHJ. Increase of donor-specific cytotoxic T lymphocyte precursors after transfusion. Transplantation 1989;48:672–5.PubMedGoogle Scholar
  18. 18.
    Van Twuyver E, Mooijaart RSD, ten Berge IJM, de Waal LP. Pretransplantation blood transfusion revisited. N Engl J Med 1991;325:1210–3.PubMedCrossRefGoogle Scholar
  19. 19.
    Lazda VA, Pollak R, Mozes MF, Barber PL, Jonasson O. Evidence that HLA class II disparity is required for induction of renal allograft enhancement by donor-specific blood transfusions in man. Transplantation 1990;49:1084–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Neefjes JJ, Ploegh HL. Assembly and intracellular transport of MHC class II molecules. Immunol Today 1992;13:179–84.PubMedCrossRefGoogle Scholar
  21. 21.
    Sheng-Tanner X, Miller RG. Correlation between lymphocyte-induced donor-specific tolerance and donor cell recirculation. J Exp Med 1992;176:407–13.PubMedCrossRefGoogle Scholar
  22. 22.
    Moretta L, Ciccone E, Moretta A, Höglund P, Öhlén C, Kärre K. Allorecognition by NK cells: Nonself or no self? Immunol Today 1992;13:300–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1993

Authors and Affiliations

  • F. H. J. Claas
  • H. S. de Koster
  • E. L. Lagaaij
  • J. J. van Rood

There are no affiliations available

Personalised recommendations